vs
CENTRUS ENERGY CORP（LEU）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CENTRUS ENERGY CORP的1.4倍（$207.3M vs $146.2M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -3.6%），CENTRUS ENERGY CORP自由现金流更多（$-58.0M vs $-100.8M），过去两年CENTRUS ENERGY CORP的营收复合增速更高（82.9% vs 38.0%）
Centrus Energy Corp是美国能源企业，主营核电站所需核燃料供应，同时专注于离心技术的研发与落地推广，生产可应用于商业、政府场景及国家安全领域的浓缩铀产品。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LEU vs RARE — 直观对比
营收规模更大
RARE
是对方的1.4倍
$146.2M
营收增速更快
RARE
高出29.5%
-3.6%
自由现金流更多
LEU
多$42.8M
$-100.8M
两年增速更快
LEU
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $146.2M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 23.9% | — |
| 营业利润率 | 8.8% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | -3.6% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.52 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LEURARE
| Q4 25 | $146.2M | $207.3M | ||
| Q3 25 | $74.9M | $159.9M | ||
| Q2 25 | $154.5M | $166.5M | ||
| Q1 25 | $73.1M | $139.3M | ||
| Q4 24 | $151.6M | $164.6M | ||
| Q3 24 | $57.7M | $139.5M | ||
| Q2 24 | $189.0M | $147.0M | ||
| Q1 24 | $43.7M | $108.8M |
净利润LEURARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $3.9M | $-180.4M | ||
| Q2 25 | $28.9M | $-115.0M | ||
| Q1 25 | $27.2M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-5.0M | $-133.5M | ||
| Q2 24 | $30.6M | $-131.6M | ||
| Q1 24 | $-6.1M | $-170.7M |
毛利率LEURARE
| Q4 25 | 23.9% | — | ||
| Q3 25 | -5.7% | — | ||
| Q2 25 | 34.9% | — | ||
| Q1 25 | 45.0% | — | ||
| Q4 24 | 40.8% | — | ||
| Q3 24 | 15.4% | — | ||
| Q2 24 | 19.3% | — | ||
| Q1 24 | 9.8% | — |
营业利润率LEURARE
| Q4 25 | 8.8% | -54.7% | ||
| Q3 25 | -22.2% | -106.9% | ||
| Q2 25 | 21.7% | -64.8% | ||
| Q1 25 | 28.0% | -102.6% | ||
| Q4 24 | 29.7% | -74.3% | ||
| Q3 24 | -13.2% | -94.6% | ||
| Q2 24 | 11.2% | -79.1% | ||
| Q1 24 | -24.3% | -151.9% |
净利率LEURARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 5.2% | -112.8% | ||
| Q2 25 | 18.7% | -69.0% | ||
| Q1 25 | 37.2% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -8.7% | -95.7% | ||
| Q2 24 | 16.2% | -89.5% | ||
| Q1 24 | -14.0% | -156.8% |
每股收益（稀释后）LEURARE
| Q4 25 | $0.52 | $-1.28 | ||
| Q3 25 | $0.19 | $-1.81 | ||
| Q2 25 | $1.59 | $-1.17 | ||
| Q1 25 | $1.60 | $-1.57 | ||
| Q4 24 | $3.26 | $-1.34 | ||
| Q3 24 | $-0.30 | $-1.40 | ||
| Q2 24 | $1.89 | $-1.52 | ||
| Q1 24 | $-0.38 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $421.0M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $765.1M | $-80.0M |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.54× | — |
8季度趋势，按日历期对齐
现金及短期投资LEURARE
| Q4 25 | $2.0B | $421.0M | ||
| Q3 25 | $1.6B | $202.5M | ||
| Q2 25 | $833.0M | $176.3M | ||
| Q1 25 | $653.0M | $127.1M | ||
| Q4 24 | $671.4M | $174.0M | ||
| Q3 24 | $194.3M | $150.6M | ||
| Q2 24 | $227.0M | $480.7M | ||
| Q1 24 | $209.3M | $112.3M |
总债务LEURARE
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $390.0M | — | ||
| Q1 25 | $389.5M | — | ||
| Q4 24 | $472.5M | — | ||
| Q3 24 | $83.5M | — | ||
| Q2 24 | $86.5M | — | ||
| Q1 24 | $86.5M | — |
股东权益LEURARE
| Q4 25 | $765.1M | $-80.0M | ||
| Q3 25 | $363.1M | $9.2M | ||
| Q2 25 | $359.1M | $151.3M | ||
| Q1 25 | $213.9M | $144.2M | ||
| Q4 24 | $161.4M | $255.0M | ||
| Q3 24 | $76.4M | $346.8M | ||
| Q2 24 | $76.6M | $432.4M | ||
| Q1 24 | $33.8M | $140.3M |
总资产LEURARE
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.2B | $1.2B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $591.0M | $1.5B | ||
| Q2 24 | $668.2M | $1.6B | ||
| Q1 24 | $750.0M | $1.3B |
负债/权益比LEURARE
| Q4 25 | 1.54× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 2.93× | — | ||
| Q3 24 | 1.09× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 2.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-58.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | -39.7% | -48.6% |
| 资本支出强度资本支出/营收 | 6.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $31.3M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流LEURARE
| Q4 25 | $-48.4M | $-99.8M | ||
| Q3 25 | $10.1M | $-91.4M | ||
| Q2 25 | $52.8M | $-108.3M | ||
| Q1 25 | $36.5M | $-166.5M | ||
| Q4 24 | $57.9M | $-79.3M | ||
| Q3 24 | $-33.2M | $-67.0M | ||
| Q2 24 | $7.0M | $-77.0M | ||
| Q1 24 | $5.3M | $-190.7M |
自由现金流LEURARE
| Q4 25 | $-58.0M | $-100.8M | ||
| Q3 25 | $5.7M | $-92.7M | ||
| Q2 25 | $49.2M | $-110.7M | ||
| Q1 25 | $34.4M | $-167.8M | ||
| Q4 24 | $57.2M | $-79.5M | ||
| Q3 24 | $-34.2M | $-68.6M | ||
| Q2 24 | $6.1M | $-79.0M | ||
| Q1 24 | $3.8M | $-193.9M |
自由现金流率LEURARE
| Q4 25 | -39.7% | -48.6% | ||
| Q3 25 | 7.6% | -58.0% | ||
| Q2 25 | 31.8% | -66.5% | ||
| Q1 25 | 47.1% | -120.5% | ||
| Q4 24 | 37.7% | -48.3% | ||
| Q3 24 | -59.3% | -49.2% | ||
| Q2 24 | 3.2% | -53.7% | ||
| Q1 24 | 8.7% | -178.2% |
资本支出强度LEURARE
| Q4 25 | 6.6% | 0.5% | ||
| Q3 25 | 5.9% | 0.8% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.9% | 1.0% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 0.5% | 1.4% | ||
| Q1 24 | 3.4% | 3.0% |
现金转化率LEURARE
| Q4 25 | — | — | ||
| Q3 25 | 2.59× | — | ||
| Q2 25 | 1.83× | — | ||
| Q1 25 | 1.34× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LEU
| Separative Work Units | $111.0M | 76% |
| Services | $21.8M | 15% |
| Other | $13.4M | 9% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
